Healthcare Sales & Marketing Network News: Letairis

Searching News Database: Letairis

HSMN NewsFeed - 22 Jul 2013
ARCA biopharma Announces Additions to GENETIC-AF Leadership Team
Biopharmaceuticals Cardiology Personnel

HSMN NewsFeed - 28 Oct 2008
Gilead Announces Two-Year Clinical Data for Letairis(R) (ambrisentan) for the Treatment of Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals

HSMN NewsFeed - 29 May 2008
Data from Pivotal Phase III Studies of Gilead's Letairis(R) (ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms Published in Circulation
Biopharmaceuticals

HSMN NewsFeed - 23 Oct 2007
Gilead Announces New LetairisTM (ambrisentan) Data for the Treatment of Patients with Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals

HSMN NewsFeed - 15 Jun 2007
U.S. Food and Drug Administration Approves Gilead's Letairis(TM) (ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatment of Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms
Biopharmaceuticals FDA

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.